Abstract
The escalating global prevalence of Type 2 Diabetes (T2D) necessitates effective management strategies. Nutraceuticals, addressing common dietary deficiencies in T2D patients, offer promising therapeutic options. Our work postulates the potential antidiabetic mechanisms underlying a combination therapy involving magnesium (Mg), cholecalciferol (CHOL), and menaquinone-7 (MK-7). We propose that this combination synergistically enhances insulin sensitivity and maintains adequate insulin secretion through diverse pathways. These include osteocalcin-mediated effects, modulation of insulin signal transduction, regulation of glucose transporters, and preservation of pancreatic β-cell mass. Elucidating these intricate mechanisms sheds light on the therapeutic efficacy of this combination therapy, paving the way for innovative interventions in T2D management.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
